Merck-AstraZeneca breast cancer drug reduces risk of death by 28% in patients diagnosed early, clinical trial shows
About 87.5% of patients treated with the drug were alive after six years, compared to 83.2% who received a placebo.
Medscape9d
Olaparib Continues to Protect Patients From High-Risk Cancer Recurrences
The benefit of the PARP inhibitor in patients with germline BRCA pathogenic variants remains evident 10 years after the first ...
Too Old to Operate3d
BRCA Reversion Mutations and Olaparib Efficacy in Relapsed Ovarian Cancer
The following is a summary of “Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive ...
Cancer therapy shows long-term survival benefits for patients with high-risk, BRCA-positive breast cancer in trial
Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to ...
News Medical10d
Olaparib provides survival benefits for high-risk BRCA-positive breast cancer patients
Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better survival outcomes than those who received placebo after a median ...
Medscape4d
Atezolizumab Plus Neoadjuvant Chemotherapy Fails to Meet Primary Endpoint in Early-Stage TNBC
The addition of atezolizumab to neoadjuvant chemotherapy failed to significantly improve event-free survival in patients with ...
Targeted Oncology10d
6-Year Data Sustain Adjuvant Olaparib Benefit in BRCA1/2+, HER2- Breast Cancer
Adjuvant olaparib continued to show a strong efficacy benefit in patients with BRCA1/2 mutation–positive, HER2-negative ...
oncnursingnews9d
Adjuvant Olaparib Continues to Improve iDFS in BRCA1/2+, HER2- Breast Cancer
Adjuvant olaparib continued to show a strong efficacy benefit in patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast, according to 6-year data from the OlympiA trial.
LYNPARZA® (olaparib) Demonstrated Clinically Meaningful Prolonged Survival Benefit in Early Breast Cancer in OlympiA Phase 3 Trial
AstraZeneca and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term results ...
HealthDay on MSN3d
San Antonio Breast Cancer Symposium, Dec. 10 to 13
San Antonio Breast Cancer Symposium was held from Dec. 10 to 13 in San Antonio. Attendees included medical oncologists, ...
Yahoo Finance11d
LYNPARZA® (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial
December 11, 2024--(BUSINESS WIRE)--Updated results from the OlympiA Phase III trial showed AstraZeneca and Merck & Co., Inc’s, known as MSD outside of the US and Canada, LYNPARZA ® (olaparib ...